What question did this study set out to answer?

To compare the outcomes and toxicities of FLAG-Ida-Ven and CLIA-Ven in treating relapsed and refractory AML during a fludarabine shortage.

FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experience

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis reveals FLAG-Ida-Ven shows better toxicity profiles than CLIA-Ven in patients with AML.

To compare the outcomes and toxicities of FLAG-Ida-Ven and CLIA-Ven in treating relapsed and refractory AML during a fludarabine shortage.
Retrospective analysis conducted at City of Hope from Dec 2020 to Jan 2023
Included patients over 18 with relapsed/refractory AML
Comparison of FLAG-Ida-Ven and CLIA-Ven regarding efficacy and toxicity
Patient demographics, treatment responses, and adverse events were documented
Overall response rate for FLAG-Ida-Ven was 46.7%, while CLIA-Ven was 75%
FLAG-Ida-Ven patients had 86% MRD negative rates versus 83% for CLIA-Ven
42% of FLAG-Ida-Ven patients and 50% of CLIA-Ven patients proceeded to allogeneic stem cell transplant
Median survival at 6 months was 48.4% for FLAG-Ida-Ven compared to 75% for CLIA-Ven
CLIA-Ven showed higher incidence of grade 3 or 4 non-hematologic adverse events (50% vs 6%)

Tinajero et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark